Domine Gomez, Manuel manuel.domine@uam.es
Actividades
- Artículos 38
- Libros 1
- Capítulos de libro 0
- Congresos 0
- Documentos de trabajo 0
- Informes técnicos 0
- Proyectos de investigación 0
- Tesis dirigidas 0
- Patentes o licencias de software 0
RET Fusion Testing with FISH and Real-Time PCR: a Comparison with RNA-Based Next-Generation Sequencing in RET Positive NSCLC
- Hernandez, S
- Carrillo, JLR
- Caminoa, A
- Benito, A
- Martinez, R
- Alonso, M
- Clave, S
- Arriola, E
- Esteban-Rodriguez, I
- De Castro, J
- Sansano, I
- Felip, E
- Abdulkader, I
- Garcia, J
- Rojo, F
- Domine, M
- Teixido, C
- Reguart, N
- Compan, D
- Insa, A
- Mancheno, N
- Palanca, S
- Juan, O
- Baixeras, N
- Nadal, E
- Cebollero, M
- Calles, A
- Martin, P
- Salas, C
- Provencio, M
- Aranda, I
- Massuti, B
- Lopez-Vilaro, L
- Majem, M
- Garrido, P
- Paz-Ares, L
- Lopez-Rios, F
- Conde, E
Journal Of Thoracic Oncology (p. S135-S136) - 1/9/2022
- ISSN 15560864
- iMarina
Addition of Immune Checkpoint Inhibitors to Chemotherapy vs Chemotherapy Alone as First-Line Treatment in Extensive-Stage Small-Cell Lung Carcinoma: A Systematic Review and Meta-Analysis
- Arriola, E
- Gonzalez-Cao, M
- Domine, M
- De Castro, J
- Cobo, M
- Bernabe, R
- Navarro, A
- Sullivan, I
- Trigo, JM
- Mosquera, J
- Crama, L
- Isla, D
Oncology And Therapy (p. 167-184) - 1/6/2022
10.1007/s40487-021-00182-0 Ver en origen
- ISSN 23661089
Multimodal prediction of response to neoadjuvant nivolumab and chemotherapy for surgically resectable stage IIIA non-small cell lung cancer.
- Ferrer, L
- Nadal, E
- Guidel, F
- Insa, A
- Menu, P
- Casal, J
- Domine, M
- Massuti, B
- Majem, M
- Martinez-Marti, A
- Campelo, RG
- Carpeon, JD
- Cobo, M
- Vivanco, GL
- del Barco, E
- Bernabe, R
- Vinolas, N
- Barneto, I
- Colin, T
- Provencio-Pulla, M
Journal Of Clinical Oncology - 1/6/2022
- ISSN 0732183X
- iMarina
Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer Who Received Adjuvant Osimertinib in the Phase III ADAURA Trial
- Majem, M
- Goldman, JW
- John, T
- Grohe, C
- Laktionov, K
- Kim, SW
- Kato, T
- Vu, HV
- Lu, S
- Li, SQ
- Lee, KY
- Akewanlop, C
- Yu, CJ
- de Marinis, F
- Bonanno, L
- Domine, M
- Shepherd, FA
- Atagi, S
- Zeng, LM
- Kulkarni, D
- Medic, N
- Tsuboi, M
- Herbst, RS
- Wu, YL
Clinical Cancer Research (p. 2286-2296) - 1/6/2022
10.1158/1078-0432.ccr-21-3530 Ver en origen
- ISSN 15573265
Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non-Small-Cell Lung Cancer (NADIM phase II trial)
- Provencio M
- Serna-Blasco R
- Nadal E
- Insa A
- García-Campelo MR
- Casal Rubio J
- Dómine M
- Majem M
- Rodríguez-Abreu D
- Martínez-Martí A
- De Castro Carpeño J
- Cobo M
- López Vivanco G
- Del Barco E
- Bernabé Caro R
- Viñolas N
- Barneto Aranda I
- Viteri S
- Pereira E
- Royuela A
- Calvo V
- Martín-López J
- García-García F
- Casarrubios M
- Franco F
- Sánchez-Herrero E
- Massuti B
- Cruz-Bermúdez A
- Romero A
Journal Of Clinical Oncology (p. 2924-2933) - 1/5/2022
10.1200/jco.21.02660 Ver en origen
- ISSN 0732183X
Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC
- Wu, YL
- John, T
- Grohe, C
- Majem, M
- Goldman, JW
- Kim, SW
- Kato, T
- Laktionov, K
- Vu, HV
- Wang, ZJ
- Lu, S
- Lee, KY
- Akewanlop, C
- Yu, CJ
- de Marinis, F
- Bonanno, L
- Domine, M
- Shepherd, FA
- Zeng, LM
- Atasoy, A
- Herbst, RS
- Tsuboi, M
Journal Of Thoracic Oncology (p. 423-433) - 1/3/2022
10.1016/j.jtho.2021.10.014 Ver en origen
- ISSN 15560864
A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial
- Soo RA, Han JY, Dafni U, Cho BC, Yeo CM, Nadal E, Carcereny E, de Castro J, Sala MA, Bernabé R, Coate L, Provencio Pulla M, Garcia Campelo R, Cuffe S, Hashemi SMS, Früh M, Massuti B, Garcia-Sanchez J, Dómine M, Majem M, Sanchez-Torres JM, Britschgi C, Pless M, Dimopoulou G, Roschitzki-Voser H, Ruepp B, Rosell R, Stahel RA, Peters S, ETOP 10-16 BOOSTER Collaborators
Annals Of Oncology (p. 181-192) - 1/2/2022
10.1016/j.annonc.2021.11.010 Ver en origen
- ISSN 09237534
Determination of essential biomarkers in lung cancer: a real-world data study in Spain with demographic, clinical, epidemiological and pathological characteristics
- Provencio M
- Cobo M
- Rodriguez-Abreu D
- Calvo V
- Carcereny E
- Cantero A
- Bernabé R
- Benitez G
- Castro RL
- Massutí B
- del Barco E
- García Campelo R
- Guirado M
- Camps C
- Ortega AL
- González Larriba JL
- Sánchez A
- Casal J
- Sala MA
- Juan-Vidal O
- Bosch-Barrera J
- Oramas J
- Dómine M
- Trigo JM
- Blanco R
- Calzas J
- Morilla I
- Padilla A
- Pimentao J
- Sousa PA
- Torrente M
Bmc Cancer - 1/12/2022
10.1186/s12885-022-09830-8 Ver en origen
- ISSN 14712407
Galectin-1, a novel promising target for outcome prediction and treatment in SCLC
- Corral JM
- Puerto-Nevado LD
- Cedeño M
- Río-Vilariño A
- Mahillo-Fernández I
- Galeano C
- Baños N
- García-Foncillas J
- Dómine M
- Cebrián A
Biomedicine & Pharmacotherapy (p. 113987-113987) - 1/12/2022
- ISSN 07533322
- iMarina
Identification of ALK-positive patients with advanced NSCLC and real-world clinical experience with crizotinib in Spain (IDEALK study)
- de la Rosa, CA
- Castellanos, PC
- Lazaro-Quintela, M
- Domine, M
- Estevez, SV
- Lopez-Vivanco, G
- Perez, JLF
- Romero, JLA
- Delgado, LF
- Giron, CG
- Tain, PD
- Alvarez, RA
- Sanchis, PM
- Canton, IF
- Abos, IM
- Aguillo, MM
- Gutierrez, LGA
- Granados, ALO
- Cabellos, RA
- Sebastian, AG
- Sifuentes, LFG
- Reguart, N
Lung Cancer (p. 83-93) - 1/11/2022
10.1016/j.lungcan.2022.09.010 Ver en origen
- ISSN 01695002
Este/a investigador/a no tiene capítulos de libro.
Este/a investigador/a no tiene congresos.
Este/a investigador/a no tiene documentos de trabajo.
Este/a investigador/a no tiene informes técnicos.
Este/a investigador/a no tiene proyectos de investigación.
Este/a investigador/a no tiene tesis dirigidas.
Este/a investigador/a no tiene patentes o licencias de software.
Perfiles de investigador/a
-
ORCID
-
Scopus Author ID
-
Dialnet id